Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265291 · ClinicalTrials.gov registry record · Phase 2
Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group
A Phase 2 study, sponsored by National Institute of General Medical Sciences (NIGMS).
- Completed
- Registry status
- Phase 2
- Development phase
- 700
- Enrollment target
NCT00265291: Completed Phase 2 study, sponsored by National Institute of General Medical Sciences (NIGMS).
NCT00265291 is a Phase 2 study that has completed, run by National Institute of General Medical Sciences (NIGMS). The registered enrollment target is 700 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (426% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00265291, a Phase 2 study, has completed, sponsored by National Institute of General Medical Sciences (NIGMS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 700 participants
- Enrollment target
Study Summary
Our goal is to study pharmacogenetics in Mexican-Americans, using depression treatments as a proof of the concept that pharmacogenetic approaches can be used to optimize treatment strategies for common and complex disorders in this population.
Interventions
- DRUG fluoxetine or desipramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 1999-11 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00265291 record still lists
NCT00265291 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (426% higher).
The record links to 0 conditions, and to 1 intervention - of which fluoxetine or desipramine is the first listed.
NCT00265291 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00265291 about?
NCT00265291 is a clinical study titled "Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group". Our goal is to study pharmacogenetics in Mexican-Americans, using depression treatments as a proof of the concept that pharmacogenetic approaches can be used to optimize treatment strategies for common and complex disorders in this population.
What is the current status of trial NCT00265291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 700 participants. The study started on 1999-11. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00265291?
The interventions under investigation include: fluoxetine or desipramine (DRUG).
Who is sponsoring clinical trial NCT00265291?
This trial is sponsored by National Institute of General Medical Sciences (NIGMS), which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00265291's enrollment target sits among peer trials
700 46th of 2000 higher than 1,955 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia